Influence of CYP2C19 Polymorphism on Lansoprazole and Rabeprazole Maintenance Treatment of Reflux Esophagitis

被引：0
作者：
Koike, Tomoyuki
Iijima, Katsunori
Imatani, Akira
Shimosegawa, Tooru
机构：
来源：
GASTROENTEROLOGY | 2010年 / 138卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
W1117
引用
收藏
页码：S655 / S655
页数：1
相关论文
共 50 条
[41]   Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication [J].
Ozdil, Burhan ;
Akkiz, Hikmet ;
Bayram, Suleyman ;
Bekar, Aynur ;
Akgollu, Ersin ;
Sandikci, Macit .
TURKISH JOURNAL OF GASTROENTEROLOGY, 2010, 21 (01) :23-28
[42]   CYP2C19 gene polymorphism in Ningxia [J].
Zhen Yang ;
Yunqian Xie ;
Daya Zhang ;
Yan Zou ;
Ximei Li ;
Runxiang Chen ;
Xiaodong Zhang ;
Shiju Chen ;
Feihu Bai .
Pharmacological Reports, 2023, 75 :705-714
[43]   CYP2C19 gene polymorphism in Ningxia [J].
Yang, Zhen ;
Xie, Yunqian ;
Zhang, Daya ;
Zou, Yan ;
Li, Ximei ;
Chen, Runxiang ;
Zhang, Xiaodong ;
Chen, Shiju ;
Bai, Feihu .
PHARMACOLOGICAL REPORTS, 2023, 75 (03) :705-714
[44]   Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism [J].
Medina J.F. ;
Lecanda J. ;
Acín A. ;
Ciesielczyk P. ;
Prieto J. .
European Journal of Clinical Pharmacology, 2001, 57 (6) :485-492
[45]   Influence of CYP2C19 Polymorphism on the Gut Microbiome in Helicobacter pylori-Negative Healthy Individuals Receiving Vonoprazan and Lansoprazole [J].
Otsuka, Taketo ;
Sugimoto, Mitsushige ;
Inoue, Ryo ;
Ohno, Masashi ;
Ban, Hiromitsu ;
Nishida, Atsushi ;
Inatomi, Osamu ;
Naito, Yuji ;
Andoh, Akira .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 :S678-S678
[46]   Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism [J].
Ieiri, I ;
Kishimoto, Y ;
Okochi, H ;
Momiyama, K ;
Morita, T ;
Kitano, M ;
Morisawa, T ;
Fukushima, Y ;
Nakagawa, K ;
Hasegawa, J ;
Otsubo, K ;
Ishizaki, T .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (6-7) :485-492
[47]   The Association Between CYP2C19 Gene Polymorphism and Response to Treatment With Pantoprazole in Patients With Gastroesophageal Reflux Disease [J].
Altinbas, Akif ;
Ekiz, Fuat ;
Goktas, Mustafa ;
Karaca, Ozgur ;
Yilmaz, Baris ;
Yasar, Umit ;
Coban, Sahin ;
Babaoglu, Melih ;
Bozkurt, Atilla ;
Yuksel, Osman .
GASTROENTEROLOGY, 2013, 144 (05) :S859-S859
[48]   Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects [J].
Zhang, Dan ;
Wang, Xiaolin ;
Yang, Man ;
Wang, Guocai ;
Liu, Huichen .
XENOBIOTICA, 2011, 41 (06) :511-517
[49]   CYP2C19 genotype does not have a significant pharmacokinetic influence in sodium rabeprazole. [J].
Aoyama, N ;
Sakai, T ;
Sakaeda, T ;
Shirasaka, D ;
Miyamoto, M ;
Kasuga, M .
GASTROENTEROLOGY, 2000, 118 (04) :A1211-A1211
[50]   The effect of CYP2C19 polymorphism on the pharmacokinetics and acid-inhibitory effects of oral lansoprazole and omeprazole [J].
Bekkers, CHJ ;
Touw, DJ ;
Lamers, CBHW ;
Geus, WP .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (05) :553-553
12345